# US 2008/0306077 A1 · Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306077 A1
- Document ID: US20080306077A1
- Status: Published application
- Kind: A1
- Application number: 12/134,553
- Filed: 2008-06-06
- Published: 2008-12-11
- Earliest claimed: 2007-06-07
- Assignees: AstraZeneca AB
- Inventors: Joshua Clayton; Ian Egle; James Empfield; James Folmer; Methvin Isaac; Fupeng Ma; Abdelmalik Slassi
- Web page: https://patentgrep.com/patent/US20080306077A1

## CPC

- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/14: containing three or more hetero rings
- C07D 487/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula I: wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

## Claims

### Claim 1

A compound according to Formula I:
wherein
R1 is halo or C1-3haloalkoxyl;
Q is
and
R2 is hydrogen or C1-3alkyl, or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer, or combination thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R1 is chloro or trifluoromethoxyl or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer thereof.

### Claim 3 (depends on 2)

A compound according to claim 2, wherein R1 is trifluoromethoxyl or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer thereof.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein Q is
or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer thereof.

### Claim 5 (depends on 4)

A compound according to claim 4, wherein Q is
and R2 is H or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer thereof.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein R1 is chloro or trifluoromethoxyl and Q is
or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer thereof.

### Claim 7 (depends on 6)

A compound according to claim 6, wherein R1 is trifluoromethoxyl and Q is
or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer thereof.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein R1 is chloro or trifluoromethoxyl, Q is
wherein R2 is H, or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer thereof.

### Claim 9 (depends on 1)

A compound according to claim 1, wherein R1 is chloro or trifluoromethoxyl and Q is
or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer thereof.

### Claim 10 (depends on 1)

A compound according to claim 1 selected from:
7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one;
2-(4-chloro-benzyl)-5-[3-(2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl)-[1,2,4]oxadiazol-5-yl]-7-methyl-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(3-methyl-piperazin-1-ylmethyl)-[1,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2,3-dihydro-isoindol-1-one;
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)-[1,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one, or
2-(4-chloro-benzyl)-7-methyl-5-[3-(2-methyl-piperazin-1-ylmethyl)-[1,2,4]oxadiazol-5-yl]-2,3-dihydro-isoindol-1-one.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim at position 12

12-14. (canceled)

### Claim 15 (depends on 1)

A method for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction in an animal in need of such treatment, comprising the step of administering to said animal a therapeutically effective amount of a compound according to claim 1.

### Claim 16 (depends on 11)

A method for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction in an animal in need of such treatment, comprising the step of administering to said animal a therapeutically effective amount of a pharmaceutical composition according to claim 11.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the neurological and psychiatric disorders are selected from cerebral deficit subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia, AIDS-induced dementia, Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, idiopathic and drug-induced Parkinson's disease, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, cerebral deficits secondary to prolonged status epilepticus, migraine, migraine headache, urinary incontinence, substance tolerance, substance withdrawal, psychosis, schizophrenia, anxiety, generalized anxiety disorder, panic disorder, social phobia, obsessive compulsive disorder, and post-traumatic stress disorder (PTSD), mood disorders, depression, mania, bipolar disorders, circadian rhythm disorders, jet lag, shift work, trigeminal neuralgia, hearing loss, tinnitus, macular degeneration of the eye, emesis, brain edema, pain, acute pain, chronic pain, severe pain, intractable pain, neuropathic pain, inflammatory pain, and post-traumatic pain, tardive dyskinesia, sleep disorders, narcolepsy, attention deficit/hyperactivity disorder, and conduct disorder.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the neurological and psychiatric disorders are selected from Alzheimer's disease, cerebral deficits secondary to prolonged status epilepticus, substance tolerance, substance withdrawal, psychosis, schizophrenia, anxiety, generalized anxiety disorder, panic disorder, social phobia, obsessive compulsive disorder, and post-traumatic stress disorder (PTSD), mood disorders, depression, mania, and bipolar disorders.

### Claim 19 (depends on 10)

A pharmaceutical composition comprising a compound according to claim 10 and a pharmaceutically acceptable carrier or excipient.

### Claim 20 (depends on 10)

A method for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction selected from cerebral deficit subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia, AIDS-induced dementia, Alzheimer's disease, Huntington's Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, idiopathic and drug-induced Parkinson's disease, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, cerebral deficits secondary to prolonged status epilepticus, migraine, migraine headache, urinary incontinence, substance tolerance, substance withdrawal, psychosis, schizophrenia, anxiety, generalized anxiety disorder, panic disorder, social phobia, obsessive compulsive disorder, and post-traumatic stress disorder (PTSD), mood disorders, depression, mania, bipolar disorders, circadian rhythm disorders, jet lag, shift work, trigeminal neuralgia, hearing loss, tinnitus, macular degeneration of the eye, emesis, brain edema, pain, acute pain, chronic pain, severe pain, intractable pain, neuropathic pain, inflammatory pain, and post-traumatic pain, tardive dyskinesia, sleep disorders, narcolepsy, attention deficit/hyperactivity disorder, and conduct disorder, in an animal in need of such treatment, comprising the step of administering to said animal a therapeutically effective amount of a compound according to claim 10.
